{"id":"polidocanol-injectable-foam-1-0","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Pain"},{"rate":"5-10%","effect":"Swelling"},{"rate":"5-10%","effect":"Redness"},{"rate":"5-10%","effect":"Itching"},{"rate":"1-5%","effect":"Numbness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process is thought to occur through the formation of a thrombus, which eventually leads to the occlusion of the treated vein. The exact molecular mechanisms underlying this process are not fully understood.","oneSentence":"Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:24.208Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of varicose veins and spider veins"}]},"trialDetails":[{"nctId":"NCT01072877","phase":"PHASE3","title":"Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-12","conditions":"Varicose Veins","enrollment":279},{"nctId":"NCT01231373","phase":"PHASE3","title":"Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-11","conditions":"Varicose Veins","enrollment":235},{"nctId":"NCT01197833","phase":"PHASE3","title":"Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-09","conditions":"Great Saphenous Vein Incompetence, Visible Varicosities","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"polidocanol injectable foam, 1.0%","genericName":"polidocanol injectable foam, 1.0%","companyName":"Boston Scientific Corporation","companyId":"boston-scientific-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure. Used for Treatment of varicose veins and spider veins.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}